老视药物疗法的研究进展  

Advances in pharmacological treatments for prebyopia

作　　者：刘德海 刘一昀 蓝倩倩 孙彤[1] 边林博 秦锐 邱磊 周一凡 齐虹 Liu Dehai;Liu Yiyun;Lan Qianqian;Sun Tong;Bian Linbo;Qin Rui;Qiu Lei;Zhou Yifan;Qi Hong(Department of Ophthalmology,Peking University Third Hospital,Beijing Key Laboratory of Restoration of Damaged Ocular Nerve,Beijing 100191,China;Department of Ophthalmology,The People′s Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,China)

机构地区：[1]北京大学第三医院眼科眼部神经损伤的重建保护与康复北京市重点实验室,100191 [2]广西壮族自治区人民医院眼科,南宁530021

出　　处：《中华眼科医学杂志（电子版）》2023年第3期177-182,共6页Chinese Journal of Ophthalmologic Medicine(Electronic Edition)

基　　金：广西医疗卫生适宜技术开发与推广应用项目(S2020077)。

摘　　要：老视是指因年龄增长所致的不可逆性生理性调节减弱,并严重影响患者视觉质量的现象。未经恰当矫正的老视是全球人口视力受损的首要因素。近年来,框架眼镜、手术及角膜接触镜等传统矫正方案已不能满足老视人群日益增长的需求,药物治疗老视可能是其新方案。本文中笔者对老视药物的应用现状和发展策略进行综述,旨在比较现有药物的有效性与安全性,并提出未来新药开发的潜在方向。Presbyopia is the irreversible loss of the accommodative ability of the eye that occurs due to ageing, which severely affects patients′ visual quality. Globally, presbyopia without proper correction is the primary cause of visual impairment. Despite widespread use of glasses, surgery and contact lens, there has been an increasing demand for novel treatment strategies. Recently, the pharmacological treatments for presbyopia provide an alternative strategy. The current status and evolving strategies of pharmacological approaches to the treatment of presbyopia were reviewed, aiming to compare the safety and efficiency of current therapies and put forward potential drug candidates.

关 键 词：老视 调节 药物治疗 毛果芸香碱 硫辛酸 

分 类 号：R77[医药卫生—眼科]